Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05587361
PHASE4

Beta-Adrenergic Modulation of Drug Cue Reactivity

Sponsor: University of Oklahoma

View on ClinicalTrials.gov

Summary

This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.

Official title: Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms

Key Details

Gender

All

Age Range

21 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2024-11-26

Completion Date

2026-03-01

Last Updated

2025-02-20

Healthy Volunteers

Yes

Interventions

DRUG

Propranolol

Propranolol Capsule; 40 mg IR

DRUG

Nicotine Patch

Nicotine Patch; 14 mg

DRUG

Placebo Propranolol

Placebo Capsule, no active ingredients

DRUG

Placebo Patch

Placebo Patch, no active ingredients

Locations (1)

Hardesty Center for Clinical Research and Neuroscience

Tulsa, Oklahoma, United States